Short Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Increases By 31.0%

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 5,830,000 shares, an increase of 31.0% from the April 30th total of 4,450,000 shares. Approximately 2.6% of the company's stock are sold short. Based on an average trading volume of 1,940,000 shares, the days-to-cover ratio is currently 3.0 days.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP raised its holdings in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after buying an additional 19,146 shares in the last quarter. Virtu Financial LLC raised its stake in Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after acquiring an additional 21,688 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 28,526 shares during the last quarter. Rock Springs Capital Management LP lifted its holdings in shares of Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after acquiring an additional 58,000 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its stake in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 58,787 shares in the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Price Performance

Shares of ADAP stock traded up $0.00 during trading on Tuesday, hitting $0.29. The company had a trading volume of 458,082 shares, compared to its average volume of 1,742,260. The firm has a market capitalization of $76.55 million, a P/E ratio of -1.31 and a beta of 2.86. Adaptimmune Therapeutics has a one year low of $0.20 and a one year high of $1.48. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The stock's 50-day moving average price is $0.26 and its 200 day moving average price is $0.46.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). The firm had revenue of $7.29 million during the quarter, compared to the consensus estimate of $6.55 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. Equities analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Barclays cut their price objective on Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a report on Wednesday, May 14th. Wall Street Zen initiated coverage on Adaptimmune Therapeutics in a research note on Friday, May 16th. They issued a "buy" rating on the stock. Wells Fargo & Company decreased their price target on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 14th. HC Wainwright cut their price objective on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Guggenheim decreased their target price on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $1.52.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.